Towards precision medicine in diabetes? A critical review of glucotypes

Adam Hulman, Yuri D Foreman, Martijn C G J Brouwers, Abraham A Kroon, Koen D Reesink, Pieter C Dagnelie, Carla J H van der Kallen, Marleen M J van Greevenbroek, Kristine Færch, Dorte Vistisen, Marit E Jørgensen, Coen D A Stehouwer, Daniel R Witte, Adam Hulman, Yuri D Foreman, Martijn C G J Brouwers, Abraham A Kroon, Koen D Reesink, Pieter C Dagnelie, Carla J H van der Kallen, Marleen M J van Greevenbroek, Kristine Færch, Dorte Vistisen, Marit E Jørgensen, Coen D A Stehouwer, Daniel R Witte

Abstract

In response to a study previously published in PLOS Biology, this Formal Comment thoroughly examines the concept of 'glucotypes' with regard to its generalisability, interpretability and relationship to more traditional measures used to describe data from continuous glucose monitoring.

Trial registration: ClinicalTrials.gov NCT02695810.

Conflict of interest statement

The authors have declared that no competing interest exists.

Figures

Fig 1. Example CGM profiles of participants…
Fig 1. Example CGM profiles of participants in the PRE-D Trial with corresponding proportion of time spent in different glucotypes and conventional measures (mean and CV).
CGM, continuous glucose monitoring; CV, coefficient of variation.
Fig 2
Fig 2
Observed proportion of time spent in the 3 glucotypes by mean CGM glucose (A) and coefficient of variation (B) in The Maastricht Study, and by mean CGM glucose in the PRE-D Trial (C) alongside predicted proportions based on the regression analysis in The Maastricht Study. CGM, continuous glucose monitoring.

References

    1. Fitipaldi H, McCarthy MI, Florez JC, Franks PW. A global overview of precision medicine in type 2 diabetes. Diabetes. 2018;67:1911–22. 10.2337/dbi17-0045
    1. Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al.. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9. 10.1016/S2213-8587(18)30051-2
    1. Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, et al.. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 2018;16:e2005143. 10.1371/journal.pbio.2005143
    1. Hulman A, Witte DR, Vistisen D, Balkau B, Dekker JM, Herder C, et al.. Pathophysiological characteristics underlying different glucose response curves: A latent class trajectory analysis from the prospective EGIR-RISC Study. Diabetes Care. 2018;41:1740–8. 10.2337/dc18-0279
    1. Zaccardi F, Khunti K. Glucose dysregulation phenotypes—time to improve outcomes. Nat Rev Endocrinol. 2018;14:632–3. 10.1038/s41574-018-0092-3
    1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44–56. 10.1038/s41591-018-0300-7
    1. Hamideh D, Arellano B, Topol EJ, Steinhubl SR. Your digital nutritionist. Lancet. 2019;393:19. 10.1016/S0140-6736(18)33170-2
    1. Li J, Li X, Zhang S, Snyder M. Gene-Environment Interaction in the Era of Precision Medicine. Cell. 2019;177:38–44. 10.1016/j.cell.2019.03.004
    1. Foreman YD, Brouwers MCGJ, van der Kallen CJH, Pagen DME, van Greevenbroek MMJ, Henry RMA, et al.. Glucose Variability Assessed with Continuous Glucose Monitoring: Reliability, Reference Values, and Correlations with Established Glycemic Indices-The Maastricht Study. Diabetes Technol Ther. 2020;22:395–403.
    1. Færch K, Amadid H, Nielsen LB, Ried-Larsen M, Karstoft K, Persson F, et al.. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). BMJ Open. 2017;7:e013802. 10.1136/bmjopen-2016-013802
    1. Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019;7:442–51. 10.1016/S2213-8587(19)30087-7
    1. Lennon H, Kelly S, Sperrin M, Buchan I, Cross AJ, Leitzmann M, et al.. Framework to construct and interpret latent class trajectory modelling. BMJ Open. 2018;8:e020683. 10.1136/bmjopen-2017-020683
    1. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med. 2008;358:580–91. 10.1056/NEJMoa0706245
    1. Vas PRJ, Alberti KG, Edmonds ME. Prediabetes: moving away from a glucocentric definition. Lancet Diabetes Endocrinol. 2017;5:848–9. 10.1016/S2213-8587(17)30234-6

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere